American Diabetes Association (ADA) June 2011

Abstracts

Treatment Satisfaction in Adults with Type 1 Diabetes Using Mealtime Inhaled Technosphere^® Insulin (Afrezza^®) in Combination with Insulin Glargine (Lantus^®) Versus Insulin Lispro (Humalog®) in Combination with Glargine. R. Petrucci, M. Peyrot, R. Rubin

ADA2011940P_IITQABSTRACT.pdf

Analysis of Cardiovascular Adverse Events in Patients with Type 1 or Type 2 Diabetes Enrolled in Selected Therapeutic Trials in the Phase 2/3 Technosphere^®Insulin Development Program. D.Bilheimer, H. Ren, A. Boss

ADA2011922P_CardioABSTRACT.pdf

No Cardiac Effects Found with Therapeutic and Supratherapeutic Doses of Technosphere® Inhalation Powder: Results from a Thorough QTc Clinical Study. R. Baughman, P. Haworth, J. Litwin, J. McDowell, J. Cassidy, A. Boss

ADA2011933P_QTcABSTRACT.pdf

ECLIA or RIA for Insulin Analysis in Pharmacokinetic and Bioequivalence Trials? J. Cassidy, S. Luzio, M. Marino, R. Baughman

ECLIAvsRIAADA2011.pdf

Doppler Echocardiography in Patients with Type 1 Diabetes Treated with Technosphere^® Insulin
N. Amin, P. Chang, R. Petrucci, P. Richardson

EchoADA2011.pdf

Technosphere^® Insulin Vs Insulin Lispro in Patients with Type 1 Diabetes Using Multiple Daily Injections. S. Garg, J. McGill, J. Rosenstock, I. Hirsch, R. Petrucci, P. Chang, A. Boss, P. Richardson, J. Skyler

ADA2011917P_117ABSTRACT.pdf

Treat-to-Target Technosphere^®Insulin in Patients with Type 1 Diabetes. S. Garg, W. Kelly, B. Freson, R. Petrucci, P. Ritchie

ADA2011941P_159ABSTRACT.pdf